Short answer · Medically reviewed summary · Last updated: 2026-05-08
Polyarteritis nodosa (PAN) was first described in 1866 by physicians Adolf Kussmaul and Rudolf Maier, who identified the condition through the presence of characteristic arterial nodules during autopsies. Since its discovery, our understanding of Polyarteritis nodosa has shifted from a fatal, poorly understood systemic disease to a manageable condition thanks to the introduction of corticosteroids and immunosuppressive therapies. When was Polyarteritis nodosa first identified? The history of Polyarteritis nodosa began in 1866, when Kussmaul and Maier termed the condition "periarteritis nodosa" because they believed the inflammation primarily affected the outer layers of the arteries.
1 people with Polyarteritis Nodosa have shared their first-person experience on this question at DiseaseMaps.
What is the history of Polyarteritis Nodosa?
History of Polyarteritis Nodosa: when and how it was discovered, and the milestones in research since, medically reviewed.
Polyarteritis nodosa (PAN) was first described in 1866 by physicians Adolf Kussmaul and Rudolf Maier, who identified the condition through the presence of characteristic arterial nodules during autopsies. Since its discovery, our understanding of Polyarteritis nodosa has shifted from a fatal, poorly understood systemic disease to a manageable condition thanks to the introduction of corticosteroids and immunosuppressive therapies.
When was Polyarteritis nodosa first identified?
The history of Polyarteritis nodosa began in 1866, when Kussmaul and Maier termed the condition "periarteritis nodosa" because they believed the inflammation primarily affected the outer layers of the arteries. It was not until later that researchers realized the inflammation actually involved all layers of the vessel wall, leading to the more accurate modern name, Polyarteritis nodosa.
How has the medical understanding of this disease evolved?
For nearly a century, Polyarteritis nodosa was often conflated with other forms of vasculitis. A major turning point occurred in the 1950s with the recognition that PAN is a distinct necrotizing vasculitis that typically spares the lungs. The clinical landscape changed significantly following these breakthroughs:
- 1940s-1950s: The introduction of corticosteroids transformed Polyarteritis nodosa from a uniformly fatal diagnosis into a treatable chronic condition.
- 1970s: The discovery of the link between Hepatitis B virus and a subset of patients helped refine diagnostic criteria.
- 1990s: The Chapel Hill Consensus Conference provided standardized nomenclature, helping distinguish Polyarteritis nodosa from microscopic polyangiitis and other related disorders.
How have technology and patient advocacy changed the landscape?
Modern diagnostic tools, such as high-resolution angiography and refined biopsy techniques, allow for earlier detection of Polyarteritis nodosa. Furthermore, the rise of digital communities like DiseaseMaps.org—where 57 individuals currently share their experiences—has fostered global patient advocacy. This collective voice has been instrumental in shifting clinical focus toward long-term quality of life and the management of treatment-related side effects.
Next steps
- Consult a rheumatologist or vasculitis specialist to discuss current evidence-based treatment protocols.
- Connect with the 57 members of the DiseaseMaps.org community to share experiences and coping strategies.
- Stay informed about clinical trials and research updates via the Vasculitis Foundation.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Polyarteritis nodosa.
- Orphanet: Polyarteritis nodosa (ORPHA:2899).
- OMIM (Online Mendelian Inheritance in Man): Polyarteritis nodosa entry.
- The Vasculitis Foundation: History and patient resources.
It was discovered in 1866 by Kussmaul and Maier during the autopsy of a patient with fever,weight loss, abdominal pain and poly neuropathy revealed areas of focal inflammatory exudations that gave rise to palpable nodules along the course of medium- sized arteries.
Posted Mar 31, 2018 by Verna 3000
